[go: up one dir, main page]

DE60127933D1 - Chimäre proteine und anwendungen - Google Patents

Chimäre proteine und anwendungen

Info

Publication number
DE60127933D1
DE60127933D1 DE60127933T DE60127933T DE60127933D1 DE 60127933 D1 DE60127933 D1 DE 60127933D1 DE 60127933 T DE60127933 T DE 60127933T DE 60127933 T DE60127933 T DE 60127933T DE 60127933 D1 DE60127933 D1 DE 60127933D1
Authority
DE
Germany
Prior art keywords
cell
proteins
disclosed
trans signal
chimeric proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60127933T
Other languages
English (en)
Other versions
DE60127933T2 (de
Inventor
Mark L Tykocinski
Jui-Han Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TYKOCINSKI, MARK L., MERION STATION, PA. 19066, US
Original Assignee
TR Associates LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TR Associates LLC filed Critical TR Associates LLC
Application granted granted Critical
Publication of DE60127933D1 publication Critical patent/DE60127933D1/de
Publication of DE60127933T2 publication Critical patent/DE60127933T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60127933T 2000-01-03 2001-01-03 Chimäre proteine und anwendungen Expired - Lifetime DE60127933T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17425800P 2000-01-03 2000-01-03
US174258P 2000-01-03
PCT/US2001/000145 WO2001049318A1 (en) 2000-01-03 2001-01-03 Novel chimeric proteins and methods for using the same

Publications (2)

Publication Number Publication Date
DE60127933D1 true DE60127933D1 (de) 2007-05-31
DE60127933T2 DE60127933T2 (de) 2008-02-07

Family

ID=22635474

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60127933T Expired - Lifetime DE60127933T2 (de) 2000-01-03 2001-01-03 Chimäre proteine und anwendungen

Country Status (10)

Country Link
US (1) US7569663B2 (de)
EP (2) EP1908780B1 (de)
JP (1) JP4723782B2 (de)
AT (1) ATE360031T1 (de)
AU (1) AU2926401A (de)
CA (1) CA2395945C (de)
DE (1) DE60127933T2 (de)
ES (1) ES2391760T3 (de)
IL (2) IL150571A0 (de)
WO (1) WO2001049318A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
HK1038755A1 (zh) * 1999-01-15 2002-03-28 Biogen, Inc. Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
NZ522741A (en) * 2000-05-08 2005-06-24 Biogen Idec Inc Method for promoting neovascularization using a TWEAK agonist and an angiogenic factor, such as fibroblast growth factor and VEGF
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
MX352180B (es) 2002-04-09 2017-11-13 Biogen Ma Inc El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak.
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
WO2005012363A1 (ja) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. 標的化された炎症惹起剤
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP2641913B1 (de) 2007-06-01 2018-04-18 University of Maryland, Baltimore Fc-rezeptor-bindemittel für konstante Immunoglobulinregion
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
EP4331604B9 (de) 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anti-pd-l1-antikörper und deren verwendung zur verbesserung der t-zellfunktion
CA2755198A1 (en) 2009-03-13 2010-09-16 Mark L. Tykocinski Ox40/trail fusion proteins
MX347343B (es) 2010-07-28 2017-04-21 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
ES2888651T3 (es) * 2011-07-29 2022-01-05 Univ Pennsylvania Receptores de conmutación coestimulantes
AU2013211824B2 (en) * 2012-01-27 2017-06-01 Gliknik Inc. Fusion proteins comprising IgG2 hinge domains
JP2015527366A (ja) 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CN105026424A (zh) 2013-01-01 2015-11-04 卡尔医疗有限公司 稳定形式的信号转化蛋白融合蛋白、及其使用和制备的方法
EP2951209A4 (de) 2013-01-31 2016-06-22 Univ Jefferson Agonistenfusionsprotein für cd40-ox40 und verwendungen davon
US9657082B2 (en) 2013-01-31 2017-05-23 Thomas Jefferson University PD-L1 and PD-L2-based fusion proteins and uses thereof
US20180169183A1 (en) * 2015-03-03 2018-06-21 Kahr Medical Ltd Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases
CN106046170B (zh) * 2015-04-10 2020-07-10 中国医学科学院药物研究所 一种新型trail融合蛋白
US11319359B2 (en) 2015-04-17 2022-05-03 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
IL256879B2 (en) 2015-07-24 2024-05-01 Gliknik Inc Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding
SG10201913573UA (en) 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
EP3439675A4 (de) 2016-04-08 2019-12-18 Purdue Research Foundation Verfahren und zusammensetzungen für car-t-zelltherapie
EP3464347B1 (de) 2016-06-07 2023-05-31 Gliknik Inc. Cystein-optimierte stradomere
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
KR20190093186A (ko) 2016-12-09 2019-08-08 글리크닉 인코포레이티드 다가 Fc 화합물에 의해 염증성 장애를 치료하는 방법
CA3047708A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirpalpha-41bbl fusion protein and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
CN110536693B (zh) 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
MY207687A (en) 2017-02-27 2025-03-12 Shattuck Labs Inc Tigit- and light-based chimeric proteins
KR20190124247A (ko) 2017-02-27 2019-11-04 샤턱 랩스 인코포레이티드 Csf1r-기반 키메라 단백질
CN118184797A (zh) 2017-02-27 2024-06-14 沙塔克实验室有限公司 基于vsig8的嵌合蛋白
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
CN107267619A (zh) * 2017-07-04 2017-10-20 武汉波睿达生物科技有限公司 一种检测靶向cd33的cart细胞中car表达的荧光定量试剂盒
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
CA3087149A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
EP3749695A4 (de) 2018-02-06 2021-12-29 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Fluorescein-spezifische car, die eine optimale t-zell-funktion gegen fl-ple-markierte tumore aufweisen
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
MX2021000047A (es) 2018-07-11 2021-05-12 Kahr Medical Ltd Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
BR112022000319A2 (pt) 2019-07-11 2022-03-15 Kahr Medical Ltd Heterodímeros e métodos de uso dos mesmos
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
EP4384280A4 (de) * 2021-08-12 2025-10-01 Baylor College Medicine Manipulierte lösliche decoy-rezeptoren zur verbesserung der krebsimmuntherapie

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000078I2 (de) * 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6632789B1 (en) * 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
GB9523469D0 (en) * 1995-11-16 1996-01-17 Sandoz Ltd Organic compounds
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US6060054A (en) * 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.

Also Published As

Publication number Publication date
ES2391760T3 (es) 2012-11-29
US7569663B2 (en) 2009-08-04
EP1248645A4 (de) 2003-08-06
IL150571A (en) 2010-11-30
JP4723782B2 (ja) 2011-07-13
AU2926401A (en) 2001-07-16
US20030216546A1 (en) 2003-11-20
WO2001049318A1 (en) 2001-07-12
ATE360031T1 (de) 2007-05-15
DE60127933T2 (de) 2008-02-07
CA2395945C (en) 2013-12-24
JP2003521485A (ja) 2003-07-15
EP1248645A1 (de) 2002-10-16
EP1908780B1 (de) 2012-08-15
CA2395945A1 (en) 2001-07-12
EP1908780A1 (de) 2008-04-09
IL150571A0 (en) 2003-02-12
EP1248645B1 (de) 2007-04-18

Similar Documents

Publication Publication Date Title
ATE360031T1 (de) Chimäre proteine und anwendungen
UA90657C2 (ru) Ловушки vegf и их терапевтические применения
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
AU2003228962A1 (en) Ferritin fusion proteins for use in vaccines and other applications
EP2277889A3 (de) Fusionsproteine von Albumin und Interferon beta
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
AU2002305450A1 (en) Proteomimetic compounds and methods
CY1108489T1 (el) Παραγωγη τετρασθενων αντισωματων
DE602004011770D1 (de) Fusionsproteine
DE69426019D1 (de) Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend
EP2298355A3 (de) Albuminfusionsproteine
EP1005376A4 (de) Methoden und zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
WO2005054286A3 (en) Interleukin-11 fusion proteins
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
ATE278011T1 (de) Human dnase ii
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
ATE230027T1 (de) Menschliche dnase i varianten
MXPA03010739A (es) Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas.
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
WO2002050116A3 (en) Adhesion molecule protein
AU2001288284A1 (en) 14189, a human kinase and uses thereof
WO2002046380A3 (en) Protein kinase

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TYKOCINSKI, MARK L., MERION STATION, PA. 19066, US

8364 No opposition during term of opposition